Axim Biotechnologies Inc (AXIM) Kazanmak

AXIM Biotechnologies, Inc. operates as a biotechnology company, which engages in the development of diagnostic healthcare solutions. The company is headquartered in San Diego, California and currently employs 6 full-time employees. The company went IPO on 2013-04-09. The firm's TearScan platform enables clinicians to quantify tear biomarkers with laboratory-grade accuracy in office settings, enhancing diagnostic confidence and treatment outcomes. The firm's product portfolio falls under the Eye Health sector and consists of the two FDA cleared 510(k) tests for dry eye disease (DED) and allergic conjunctivitis, both testing tears for these diseases. The company has also internally developed an immunoassay for a potential third product which would measure MMP-9 in tears. MMP-9 is a biomarker for ocular surface inflammation and is an additional diagnostic tool for DED and other eye diseases. Its ophthalmological diagnostic tests include Ocular Immunoglobulin E (IgE) Test and Lactoferrin Test. IgE is a biomarker for allergic conjunctivitis, which often mimics dry eye disease or co-exists with dry eye disease.